PNGAF Is Coming For Big Pharma’s $82 Billion GLP-1 Market
Anyone who knows someone on Ozempic or Mounjaro knows the weekly routine of taking a pen out of the refrigerator and pushing a needle into the stomach, and most other peptides still reach people the same way. The Precision Peptide Company (CSE: $BPC) (OTCQB: $PNGAF) is replacing that routine with peptide patches that stick to the skin like a bandage and deliver a measured dose without a syringe or a refrigerator. PNGAF has four of those patches in its line with the first already selling in all 50 states, and it has locked in exclusive rights to all four at its U.S. manufacturer.
The first patch on shelves is The Recovery Patch, which sells at $375 for a two-box pack of 20 and delivers 2 mg of BPC-157, a recovery peptide athletes and biohackers have mostly injected, through a patent-pending dissolving lattice that needs no refrigeration. Independent testing by Miraxis Labs in San Diego measured 95.5% purity and 2.02 mg of BPC-157 per patch, clearing the industry's 95% benchmark for a high-purity peptide. The company took delivery of roughly 20,000 patches in July and opened nationwide sales days after an FDA advisory committee backed BPC-157 for the 503A compounding list. The second patch carries Thymosin Alpha-1, an immune-support peptide that entered formal U.S. testing in September before the company placed a 20,000-patch order due in January, making it the second peptide PNGAF has taken from formula to production.
The next two patches go after weight loss, and the first, a tirzepatide patch, has entered formal U.S. testing on the molecule Eli Lilly (NYSE: $LLY) sells as Mounjaro and Zepbound. Those two brands brought in $36.5 billion for Lilly in 2025, and the company believes it could be among the first to market with a tirzepatide patch. GLP3 joined as the fourth patch and the second built for weight management, and the company plans to take both down the same route from U.S. formulation and testing to a production order that BPC-157 and TA1 have already run. All four patches come from a U.S. manufacturer that used to be free to make similar formulas for other brands and now produces them for PNGAF alone, which ties every formula in the line to one in-house brand.
But even the best product in the world is worth nothing without the sales channels and marketing to move it, and PNGAF built its own, starting with an exclusive marketing agreement with combat sports platform MMA.INC (NYSE American: $MMA). MMA.INC counts Conor McGregor as a strategic advisor and reaches more than 5 million social followers and over 800 verified gyms, and from the partnership's second year the company keeps 75% of net revenue on every MMA-sourced sale. The company also opened a U.S. wholesale channel that lets gyms, fight academies, clinics, and med spas stock its patches and supplements, with every order shipping from its own fulfillment operation. It markets in person too, sponsoring Colorado's Boulderthon marathon weekend and the Championing Mental Health 3 boxing event and selling the Recovery Patch from its own booth at FitExpo Anaheim. Each of those channels puts the patch in front of people who train hard enough to wake up sore, the exact buyer a recovery product is made for.
The weight-loss patches aim at the largest of the company's markets, a GLP-1 receptor agonist market Grand View Research sizes at $82 billion in 2026, with North America taking 75.5% of that spending in 2025. Gallup found that 11% of U.S. adults now take a GLP-1 for weight loss, nearly four times the 2024 share, and Grand View expects online pharmacies to be the fastest-growing GLP-1 channel at 21.2% a year. The Recovery Patch and TA1 belong to a peptide therapeutics market Precedence Research sizes at $56.06 billion in 2026, and the company's capsules and copper-peptide serum sell into a U.S. dietary supplements market Grand View puts at $74.06 billion. PNGAF sells into all three from one brand, and the fastest-growing money in each is moving online, where the company already does business.
Hims & Hers (NYSE: $HIMS) grew revenue 59% to $2.35 billion in 2025 selling through its online health and wellness platform, compounded semaglutide included. PNGAF runs that kind of platform in all 50 states, where licensed physicians prescribe compounded tirzepatide and semaglutide alongside sermorelin and NAD+ protocols, and its tirzepatide patch is designed to plug into it. The two companies that built the GLP-1 market are now racing to change how patients take it, with the FDA clearing the Wegovy pill from Novo Nordisk (NYSE: $NVO) in December and approving Lilly's Foundayo tablet in April. Lilly is building a $3 billion plant in the Netherlands that will help make Foundayo, betting the next wave of patients goes to whoever makes the drug easiest to take, the same bet PNGAF is making with a patch.
CSO Justin Kirkland co-founded Amino Innovations, the peptide brand that developed the company's patch technology, and brings more than 30 years in pharmaceutical development and peptide formulation to the needle-free line. Turning that line into a consumer brand falls to Director Nashir Virani, the former CEO of Golden Boy Foods, which Post Holdings (NYSE: $POST) bought for C$320 million. Virani grew Golden Boy from a coffee business into a diversified food manufacturer before that sale, the same climb PNGAF is making as it builds from one recovery patch into a four-patch line.
PNGAF is building the trusted name in a category that has never had one, and the rules are moving its way, with federal health officials saying in February that the FDA is moving to ease its restrictions on BPC-157. The company also holds a LegitScript Healthcare Merchant Certification that clears it to take payments and run ads on the major platforms, a door the offshore vial sellers who built this category were never going to walk through. As the FDA works through the rulemaking that would add BPC-157 to the 503A list, their customers will be hunting for a U.S. brand with a lab certificate in the box and a checkout that works. PNGAF has both, and with a market cap of $10 million it is building a tirzepatide patch to take its brand into a GLP-1 market expected to reach $185.3 billion in just a few years time.
Disclaimer: Mt. Zion Market Ventures has received compensation for the creation and dissemination of this article. For more information, please visit opendisclose.com. The information provided here is not intended to be a comprehensive analysis of the subjects mentioned. All information, opinions, and forecasts contained herein should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities or related financial instruments. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions. The author and publisher of this content are not responsible for any losses, damages, or other consequences that may result from the use of the information provided. Investing in stocks, including those mentioned here, involves risks, including the risk of loss.
